Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays

J Clin Pathol. 2007 Apr;60(4):397-404. doi: 10.1136/jcp.2005.034447. Epub 2006 Jun 14.

Abstract

Aim: To assess whether immunohistochemically stained tissue microarrays (TMA) of 2 mm cores from paraffin embedded tumour tissue may replace whole sections in semi-quantitative evaluation of selected potential markers for endocrine treatment.

Methods: Whole sections and 2 mm cores on TMA were used for immunohistochemical staining of potential markers for endocrine treatment. The Allred scoring system was used for the markers with nuclear localisation: the oestrogen receptor, the progesterone receptor, p27 and the oestrogen receptor co-regulator amplified in breast cancer 1 (AIB1). The Allred scoring system was also used for the non-nuclear markers Bcl-2, pS2 and cyclooxygenase 2 (COX-2); the membrane receptors HER-2, insulin-like growth factor I receptor (IGF-IR) and epidermal growth factor receptor were quantified according to the guidelines for the Herceptest.

Results: The data and statistical analyses showed that the semi-quantitative evaluation of oestrogen receptor, progesterone receptor, AIB1, COX-2, HER-2 and IGF-IR on TMA blocks was comparable with analysis on whole sections.

Conclusions: This study shows that semi-quantitative scoring of 2 mm cores on TMA is feasible for several potential markers for endocrine therapy. Considering the small size of many breast tumours, the speed and cost-effectiveness of immunohistochemistry on TMA compared with whole sections, and the importance of the expression level of the proteins, semi-quantitative scoring on TMA has great potential in both retrospective and prospective studies aiming at improving the prediction of response to endocrine treatment.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Biomarkers, Tumor / analysis*
  • Breast Neoplasms / chemistry*
  • Breast Neoplasms / drug therapy
  • Cell Membrane / chemistry
  • Cell Nucleus / chemistry
  • Cyclooxygenase 2 / analysis
  • Cytoplasm / chemistry
  • Female
  • Histone Acetyltransferases / analysis
  • Humans
  • Immunoenzyme Techniques
  • Neoplasm Proteins / analysis*
  • Nuclear Receptor Coactivator 3
  • Receptor, ErbB-2 / analysis
  • Receptor, IGF Type 1 / analysis
  • Receptors, Estrogen / analysis
  • Receptors, Progesterone / analysis
  • Specimen Handling / methods
  • Tamoxifen / therapeutic use
  • Tissue Array Analysis / methods
  • Trans-Activators / analysis

Substances

  • Antineoplastic Agents, Hormonal
  • Biomarkers, Tumor
  • Neoplasm Proteins
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Trans-Activators
  • Tamoxifen
  • Cyclooxygenase 2
  • Histone Acetyltransferases
  • NCOA3 protein, human
  • Nuclear Receptor Coactivator 3
  • Receptor, ErbB-2
  • Receptor, IGF Type 1